Patent ID: 6949535
Filing Date: 2005-09-27
Classification: A61K,A61P,C07C,C07D,C12N,C12Y

Abstract:
1. A method of disrupting leukocyte function comprising a step of contacting leukocytes with a compound having a structure wherein A is an optionally substituted monocyclic 5-membered heterocyclic ring system containing two or three nitrogen atoms or a bicyclic ring system containing at least two nitrogen atoms, and at least one ring of the bicyclic system is aromatic; X is selected from the group consisting of C(R Y is selected from the group consisting of null, S, SO, and SO R or R R R or two R R R Het is a 5- or 6-membered heterocyclic ring, saturated or partially or fully unsaturated, containing at least one heteroatom selected from the group consisting of oxygen, nitrogen, and sulfur, selected from the group consisting of 1,3-dioxolane, 2-pyrazoline, pyrazolidine, pyrrolidine, piperazine, pyrroline, 2H-pyran, 4H-pyran, morpholine, thiomorpholine, piperidine, 1,4-dithiane, and 1,4-dioxane, and optionally substituted with C and pharmaceutically acceptable salts or solvates, in an amount sufficient to inhibit phosphatidylinositol 3-kinase delta activity in said leukocytes.